Stomach/ Gastric Cancer Clinical Trials in Georgia

Cancer Type = Stomach/ Gastric Cancer

Cancer Type = Stomach/ Gastric Cancer

There are currently 12 active Stomach/ Gastric Cancer clinical trials in Georgia.
1.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
2.
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
3.
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT02935634
Protocol IDs
CA018-003
NCI-2017-00025
2016-002807-24
4.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
5.
A Phase I / II Study of Trifluridine / Tipiracil (TAS102) in Combination with Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Cancer Type
Pancreatic Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
7.
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Cancer Type
Colon/Rectal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03783936
Protocol IDs
HCRN GI17-319
NCI-2018-03813
8.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
9.
Effects on QOL When Zinc is Supplemented in Patients with Upper GI Cancer on Chemotherapy
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT03819088
Protocol IDs
Winship4173-17
NCI-2017-02467
IRB00099791
10.
Phase 1 / 2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Cancer Type
Breast Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
11.
Phase 1 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Cancer Type
Pancreatic Cancer, Stomach/ Gastric Cancer
NCI ID
NCT02102022
Protocol IDs
POLARIS2013-001
NCI-2017-00851
12.
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Cancer Type
Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer
NCI ID
NCT02595424
Protocol IDs
EA2142
EA2142
NCI-2015-00547
NCI-2015-00505
EA2142
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.